Related references
Note: Only part of the references are listed.Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine
Daigo Yamamoto et al.
BREAST CARE (2010)
Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan
Hai-Rim Shin et al.
CANCER SCIENCE (2010)
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine
Yoshinori Ito et al.
BREAST CANCER (2009)
A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
J-L Lee et al.
BRITISH JOURNAL OF CANCER (2008)
Clinical efficacy of S-1 in pretreated metastatic breast cancer patients
Tadahiko Shien et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review
Georgios V. Koukourakis et al.
MOLECULES (2008)
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial
Daigo Yamamoto et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
P Fumoleau et al.
EUROPEAN JOURNAL OF CANCER (2004)
Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
P Reichardt et al.
ANNALS OF ONCOLOGY (2003)
Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
JA O'Shaughnessy et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
